[ad_1]
With this achievement, the Novavax vaccine is close to seeking regulatory approvals.
The company confirmed in a statement that it did not monitor severe cases of illness or deaths among those who participated in the vaccine trials, which may mean it can stop serious infections with variants of the virus.
The virus was 86 percent effective in protecting against the British strain of Coronavirus, and reached 90 percent against both ancient and British virus types.
The announcement triggered a jump in Novavax shares, reaching 22 percent, to close late Thursday at $ 229.
The value of the stock did not exceed $ 10 in January 2020, when the company announced its intention to develop a vaccine for Corona.
In a smaller experiment conducted by the company in South Africa, home to one of the newest and most infectious corona viruses, the Novavax vaccine was 55 percent effective and provided experimental participants with great protection against contracting a severe case of disease. .
According to Novavax Medical Director Philip Dubowski, the results revealed by the vaccine in Africa reflect the possibility of using it in areas where the South African virus is spreading.
In parallel with its vaccine directed at the original strain of the virus, the company is working on the development of new formulations capable of protecting against modern variables, and will begin its experiments in this regard in the second quarter of 2021.
Novavax is still awaiting its experimental data, which included about 30,000 people in the United States and Mexico, which is expected to appear in early April.
The experiment carried out by the company in Great Britain included more than 15,000 people, ranging in age from 18 to 84 years.
And if the Novavax vaccine were approved for use in the United States, it would be the fourth in the country to previously approved other vaccines developed by Moderna, Pfizer and Johnson & Johnson.
[ad_2]
